Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct;10(10):3929–3942. doi: 10.21037/tlcr-21-524

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2021 Translational Lung Cancer Research. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

Representative chest CT or ultrasound images at different stages of disease course (A-E) and timeline of therapy and disease status for both lung cancer and TB infection in patient P3 (F). Chest CT images at the initial diagnosis of lung cancer (A), after 4 cycles of neoadjuvant chemotherapy (B), and after surgery (C). (D) shows the ultrasound image of the enlarged right supraclavicular lymph node (marked with a triangle) that was confirmed as a metastatic lesion afterwards. (E) shows a novel infiltrate (marked with an arrow) after 2 cycles of immunotherapy. LUAD, lung adenocarcinoma; NACT, neoadjuvant chemotherapy; nabPTX, nanoparticle albumin-bound paclitaxel; TB, tuberculosis; HRELfx, isoniazid, rifampicin, ethambutol, and levofloxacin; HR, isoniazid and rifampicin; RSclN, right supraclavicular lymph node; PD, progression disease; PD-1, programmed cell death 1.